AB ANALITICA will be attending the AACC Annual Scientific Meeting organized annually by ADLM – Association for Diagnostics & Laboratory Medicine to be held from July 28 to August 1, 2024 in Chicago IL, USA.
Come and visit us at Booth 4953 to learn more about our products, we look forward to seeing you!
AB ANALITICA will be attending the 33rd ECCMID International Congress – European Congress of Microbiology and Infectious Diseases organized annually by ESCMID to be held from April 27 to 30, 2024 in Barcelona, Spain.
Come and visit us at Booth E70 to learn more about our products, we look forward to seeing you!
The GENEQUALITY® TWENTYFIFTY (GQ 2050) is an automated sample-to-result system, with integrated thermal cycler, for the extraction of nucleic acids from biological samples, the Real-Time PCR reactions set-up and run and the reporting of the results..
The system presents several control and safety features including:+
Additionally, the GQ 2050 is equipped with a Hepa filter for environmental safety, UV lamp and tips with filters to manage and limit potential contaminations.
See product
AB ANALITICA will be attending the 51st AMCLI Congress in Rimini from March 8 to 11, 2024.
We invite you to our stand to see our products in person and meet our team.
This year we have exciting news… are you ready to discover it?
It will be a great opportunity to see us in person, we look forward to seeing you!
Test di vitalità spermatozoaria: confronto tra Eosin test e Hypoosmotic swelling test.
Gambardella A., Tedesco A., Salierno M., Attilio R.
Prodotti citati / Cited products: FERTILITY LIFE TEST
Poster: “Design and Development of a Pharmacogenetic Molecular Test for Predicting Personalized Warfarin Dosages”
E.Bugin
Poster (cod.157): “Sviluppo e validazione di un nuovo test molecolare per l’identificazione simultanea di polimorfismi nei geni IL28B e ITPA, implicati nel trattamento farmacologico dell’epatite C”.
Autori: Bortolozzo K., Bugin E., Rosa Gastaldo L., Marcolongo M., Gonzo M., Paladin D.
Prodotto citato / Cited product: GENEQUALITY IL28B-ITPA TYPE
“WARFARIN E PEG-IFN/RBV: Sviluppo di Test Farmacogenetici per la Personalizzazione della Terapia Farmacologica”
Dottoranda: Elisabetta Bugin
Direttore della Scuola: Ch.mo Prof. Pietro Giusti
Coordinatore di Indirizzo: Ch.mo Prof. Pietro Giusti
Supervisore Interno: Ch.mo Prof. Eugenio Ragazzi, Supervisore Esterno: Dott. Dino Paladin
Prodotti citati / Cited products: GENEQUALITY AB WARFARIN TYPE
Poster: WARFARIN TYPE: Sviluppo di un test farmacogenetico per il dosaggio individuale del Warfarin(Coumadin®)
E.Bugin, K.Bortolozzo, D.Paladin, M.Pelloso, S.Moz, D.Bozzato, P.Fogar, D.Basso, CF.Zambon, M.Plebani.
Prodotto citato / Cited product: GENEQUALITY AB WARFARIN TYPE
Poster presentation at: ISMD2014 10th International Symposium on Molecular Diagnostics (May 29 – 31, 2014)
Poster (P2): “Novel pharmacogenetic test for management of antiviral therapy in patients with chronic hepatitis C”.
Bugin E., Cavalletto L., Bortolozzo K., Schiavo I., Chemello L.
Prodotto citato / Cited product: GENEQUALITY IL28B-ITPA TYPE
Abstract: Test di screening per la prevenzione dell’ipersensiblità ad Abacavir: HLA-B*57:01 o HCP5 568G?
Autori: C. Badulli, C. Pizzochero, I. Sbarsi, C. Boschetto, K. Bortolozzo, C. Daielli, L. Salvaneschi, M. Martinetti.
Prodotto citato / Cited product: GENEQUALITY HLA B*57-01
Abstract: Allelotyping HLA_B*57:01 e TAG SNPs dell’aplotipo ancestrale 57.1 come markers di esigibilità al trattamento con Abacavir.
Autori: K.Bortolozzo, C.Boschetto, S.Mason, M.Baroncelli, R.Sestini, B.Porfirio.
Prodotto citato / Cited product: GENEQUALITY HLA B*57-01
Poster : “A New and Simple Method for HLA-B*57:01 Screening Before ABACAVIR Treatment”
Autori: Bortolozzo K.; Boschetto C., Hajman K., Cesaro L., Mason S, Baroncelli M., Sestini R., Porfirio B.
Prodotto citato / Cited product: GENEQUALITY HLA B*57-01
E-Poster: Development and validation of a simple method for the detection of all HLA haplotypes associated with Celiac Disease.
Bortolozzo K.; Renesto A.; Boschetto C.; Cesaro L.; Mavilia C.; Dal Canto M.; Gabbanini F.; Como A.; Porfirio B.
Prodotto citato / Cited product: GENEQUALITY CD-TYPE
Tag SNPs of the ancestral haplotype 57.1 do not substitute HLA-B*57:01 typing for eligibility to abacavir treatment in the italian population.
Badulli C, Sestini R, Sbarsi I, Baroncelli M, Pizzochero C, Martinetti M, Porfirio B.
Prodotto citato / Cited product: GENEQUALITY HLA B*57-01
The Pharmacogenomic HLA Biomarker Associated to Adverse Abacavir Reactions: Comparative Analysis of Different Genotyping Methods.
Stocchi L, Cascella R, Zampatti S, Pirazzoli A, Novelli G, Giardina E.
Prodotto citato / cited Product: GENEQUALITY HLA B*57-01
A real-time polymerase chain reaction-based protocol for low/medium-throughput Y-chromosome microdeletions analysis.
Segat L, Padovan L, Doc D, Petix V, Morgutti M, Crovella S, Ricci G.
Prodotto citato / Cited product: GENEQUALITY AZF-MX
WINNER OF POSTER AWARDS COMPETION AT EUROMEDLAB MILANO 2013:
Atypical Cystic Fibrosis: development of a new genetic test for identification of ENaC mutations
Renesto, A., Bortolozzo, K., Albanese, A., Tamanini, A., Zampieri, C., Dechecchi, M. C.
Screening per le mutazioni del gene CFTR (Cystic Fybrosis transmembrane regulator gene) in 3.578 pazienti infertili candidati per tecniche di riproduzione assistita e relazione tra le mutazioni del cromosoma Y in maschi azoospermici.
M.Rongioletti, F.Papa, M.Cortesi, L.Bonito, V.Panetta, C.Vaccarella, T.Melillo, B.D’Andrea, P.Scotaccia, S.Cesaretta, G.M.Liumbruno.
Prodotti citati / Cited products: GENEQUALITY AZF MX
Poster presentation (P118): “A new simple method for HLA-B*5701 screening before abacavir treatment”
K.Bortolozzo, C.Boschetto, K.Hajman, L.Cesaro, S.Mason, M.Baroncelli, R.Sestini, B.Porfirio.
Prodotto citato / Cited product: GENEQUALITY HLA B*57-01
EAA/EMQN best practice guidelines for molecular diagnosis of Y-chromosomal microdeletions: state-of-the-art 2013.
Krausz C, Hoefsloot L, Simoni M, Tüttelmann F.
Prodotto citato / Cited product: GENEQUALITY AZF-MX
Poster: “Fibrosi cistica atipica: sviluppo di un nuovo kit diagnostico per l’identificazione dei polimorfismi nei geni ENaC”
Autori: A. Renesto, K. Bortolozzo, C. Savio, D. Paladin, A. Tamanini, C. Zampieri, F. Cioffi, G.Cabrini, G.C. Guidi, M.C. Dechecchi M.C.
Comunicazione orale: “Evaluation of AMPLIQUALITY HCV-TS Kit for Direct Genotyping on Amplicons Obtained by COBAS TAQMAN HCV TEST”.
Bortolozzo K.; Hajman K.; Rosa Gastaldo L.; Renesto A.; Rovinetti C.; Turi R.; Ceres A.; Capone G.; Mirandola S.; Marcolongo M.; Alberti A.; Bassetti D.; Collini L.; Lanzafame P., Bevilacqua F.
Prodotto citato / cited Product: AMPLIQUALITY HCV-TS
Poster : “Valutazione del Kit per la Genotipizzazione Diretta da Amplificato COBAS® TAQMAN® HCV Test”
Autori: Bortolozzo K.; Hajman K.; Rosa Gastaldo L.; Renesto A.; Pelizzaro R., Rovinetti C.; Turi R.; Ceres A.; Capone G.; Mirandola S.; Marcolongo M.; Alberti A.; Bassetti D.; Collini L.; Lanzafame P.,Veronesi A., Scapin L.,Bevilacqua F.
Prodotto citato / Cited product: AMPLIQUALITY HCV TS
Determination of Hepatitis C Virus Genotype Distribution in Mersin Province, Turkey – Mersin İlinde Hepatit C Virusu Genotip Dağılımının Belirlenmesi – turkish
S.Tecan, M.Ulger, G.Aslan, S.Yaras, E.Altintas, O.Sezgin, G.Emekdas,B. Gurer Giray, M.A.Singur
Prodotto citato / Cited product: AMPLIQUALITY HCV TS
Serum 90K/Mac-2 binding protein (Mac-2BP) as a response predictor to peginterferon and ribavirin combined treatment in HCV chronic patients.
Iacovazzi PA, Cozzolongo R, Lanzillotta E, Frisullo S, Guerra V, Correale M.
Prodotto citato / Cited product: AMPLIQUALITY HCV TS
Poster presentation: ” Plasminogen Activator Inhibitor-1 gene 4G/5G polymorphism in group of Serbian women with primary and secondary infertility”.
Simic Svetlana, Stevanovic Snezana, Brajic Aleksandra, Djurovic Jelena, Stamenkovic Gorana.
Prodotto citato / Cited product: REALQUALITY RS-PAI-1 4G/5G
Poster: Evaluation of AB ANALITICA RS-HEMO C282Y and H63D Real Time PCR Kits Combined With EASYMAG DNA Extraction System.
J.Gras
Prodotto citato / cited Product: REALQUALITY RS-HEMO C282Y, REALQUALITY RS-HEMO H63D
Poster presentation: “Impact of C677T polymorphism of the methylenetetrahydrofolate reductase in group of Serbian women with primary and secondary infertility”.
Brajic Aleksandra, Vuksanovic Ana, Sarkic Mirjana, Ckonjovic Miodrag, Stamenković Gorana.
Prodotto citato / Cited product: REALQUALITY RS-MTHFR C677T
Poster: “Design and Development of a Pharmacogenetic Molecular Test for Predicting Personalized Warfarin Dosages”
E.Bugin
Poster (cod.157): “Sviluppo e validazione di un nuovo test molecolare per l’identificazione simultanea di polimorfismi nei geni IL28B e ITPA, implicati nel trattamento farmacologico dell’epatite C”.
Autori: Bortolozzo K., Bugin E., Rosa Gastaldo L., Marcolongo M., Gonzo M., Paladin D.
Prodotto citato / Cited product: GENEQUALITY IL28B-ITPA TYPE
“WARFARIN E PEG-IFN/RBV: Sviluppo di Test Farmacogenetici per la Personalizzazione della Terapia Farmacologica”
Dottoranda: Elisabetta Bugin
Direttore della Scuola: Ch.mo Prof. Pietro Giusti
Coordinatore di Indirizzo: Ch.mo Prof. Pietro Giusti
Supervisore Interno: Ch.mo Prof. Eugenio Ragazzi, Supervisore Esterno: Dott. Dino Paladin
Prodotti citati / Cited products: GENEQUALITY AB WARFARIN TYPE
Poster: WARFARIN TYPE: Sviluppo di un test farmacogenetico per il dosaggio individuale del Warfarin(Coumadin®)
E.Bugin, K.Bortolozzo, D.Paladin, M.Pelloso, S.Moz, D.Bozzato, P.Fogar, D.Basso, CF.Zambon, M.Plebani.
Prodotto citato / Cited product: GENEQUALITY AB WARFARIN TYPE
Poster presentation at: ISMD2014 10th International Symposium on Molecular Diagnostics (May 29 – 31, 2014)
Poster (P2): “Novel pharmacogenetic test for management of antiviral therapy in patients with chronic hepatitis C”.
Bugin E., Cavalletto L., Bortolozzo K., Schiavo I., Chemello L.
Prodotto citato / Cited product: GENEQUALITY IL28B-ITPA TYPE
Presentazione: “12-13K-RAS kit: an IVD for the detection of mutations in the K-ras oncogene by amplification of DNA in the codon 12 and 13 region and RFLP.”
D.Paladin
Prodotto citato / Cited Product: GENEQUALITY 12-13K-RAS
“Microsatellite Instability (MSI) as Genomic Markers in Endometrial Cancer: Toward Scientific Evidences”
A.Tinelli, V.Mezzolla, G.Leo, M.Pisanò, F.Storelli, G.Alemanno, A.Malvasi, G.Ronzino and V.Lorusso.
Prodotto citato / Cited product: GENEQUALITY CC-MSI
A ten markers panel provides a more accurate and complete microsatellite instability analysis in mismatch repair-deficient colorectal tumors
M.Agostini, M.V. Enzo, L.Morandi, C.Bedin, S.Pizzini, S.Mason, R.Bertorelle, E.Urso, C.Mescoli, M.Lise, S.Pucciarelli and D.Nitti
Prodotto citato / Cited product: GENEQUALITY-CC-MSI
Promoter methylation correlates with reduced NDRG2 expression in advanced colon tumour.
Piepoli A, Cotugno R, Merla G, Gentile A, Augello B, Quitadamo M, Merla A, Panza A, Carella M, Maglietta R, D’Addabbo A, Ancona N, Fusilli S, Perri F, Andriulli A.
Prodotto citato / Cited product: GENEQUALITY CC-MSI
E-poster: “A new rapid and sensitive method for kras screening by Real Time sequence Specific Primer PCR (SSP-PCR)”
S.Marzinotto, F.Sessa, A.Franzoni, A.Anselmi, L.Rosa Gastaldo, S.Mason, G.Damante, C.A.Beltrami, and L.Mariuzzi
Poster: Identificazione di Mutazioni nei Geni KRAS e BRAF: Dispositivi Diagnostici Ultra Sensibili per la Medicina Personalizzata.
F.Sessa, A.Anselmi, I.Schiavo, S.Mason
“KRAS Codons 12 and 13 Mutation Analysis: A Comparative Study between Direct Sequencing and a New Sensitive Real-Time PCR Assay”
S.Marzinotto, F.Sessa, A.Franzoni, A.Anselmi, L.Rosa Gastaldo, S.Mason, G.Damante, C.A.Beltrami, and L.Mariuzzi
A novel cytogenetic abnormality t(7;8)(p11.2:q11.2) and a four-way Philadelphia translocation in an imatinib mesylate-resistant chronic myeloid leukemia patient.
Al-Achkar W, Aljapawe A, Almedani S, Liehr T, Wafa A.
Prodotto citato / cited Product: GENEQUALITY BCR-ABL
Primary follicular lymphoma of the epididymis positive for t(14;18)(q32;q21)/IGH-BCL2 and negative for BCL2 protein expression: a case report.
Tralongo V, Becchina G, Nagar C, Ottoveggio G, Mason S, Seno B, Sessa F, Frattini M, Genovese F.
Prodotto citato / Cited product: GENEQUALITY BCL-2
“Development of two diagnostic systems for the detection of mutations in MPL and CALR genes”.
I.Schiavo, A.Anselmi, G.Costanzi, A.Cignarella, D.Paladin.
Prodotto citato/Cited product: GENEQUALITY CALR MUTATION
Poster presentation: “Development and validation of a kit for the detection of the PML-RARA bcr2 fusion transcript for monitoring of acute promyelocytic leukemia”
I. Schiavo , A. Anselmi, F. Sessa, S. Mason, A. Cignarella.
Prodotto citato / Cited product: REALQUALITY RS-PML-RARa bcr2
Poster presentation: “Development of two diagnostic systems for the detecion of mutations in the genes MPL and CALR”.
Schiavo I., Anselmi A. Costanzi G., Guglielmelli P., Pancrazzi A., Paladin D., Vannucchi AM.
Prodotto citato / Cited product: GENEQUALITY CALR MUTATION
Poster (cod.175): “Ricerca di C.trachomatis in prelievi cervicali di donne HPV positive e negative”.
Autori: Marcante R., Fabrello L., Mason S., Gani A., Bergamin C., Antico A.
Prodotto citato / Cited product: REALQUALITY RS-CHLAM T
Poster (cod.164): “Valutazione degli IVD REALQUALITY RQ-STI AB ANALITICA nella diagnosi delle infezioni sessualmente trasmesse”.
Autori: Dirani G., Dalmo B., Strammiello R., Sambri V. Farabegoli P.
Prodotti citati / Cited products: REALQUALITY RQ-STI CT/NG, REALQUALITY RQ-STI MG/MH, REALQUALITY RQ-STI UU/UP
Pyogranulomatous panniculitis caused by Mycobacterium alvei in a cat
Beccati M, Peano A, Gallo MG.
Prodotto citato/Cited product: AMPLIQUALITY MYC-TE
Prevalence of Helicobacter pylori oral carriage in a children’s community
De Vito D., Santantonio M., Coscia M.F., Rizzo C., Monno R.A., Rizzo G.
Prodotto citato/Cited product: AMPLIQUALITY HP
Frequent detection of cytomegalovirus (CMV) DNA in the lower respiratory tract in CMV-seropositive pediatric patients with underlying chronic bronchopulmonary diseases lacking canonical immunosuppression.
Escribano, A., Chilet, M., Clari, M. Á., Lucas, R., Costa, E., Bravo, D., Muñoz-Cobo, B., Borrás, R. and Navarro, D.
Prodotto citato / cited Product: REALQUALITY RS-HHV-7, REALQUALITY RS-HHV-8
Ricerca di Chlamydia trachomatis in pazienti HPV positivi e HPV negativi.
Laureanda: Lisa Fabrello;
Relatore:Prof. Giulio Bertoloni ,
Co- Tutor: Dott. Roberto Marcante – U.L.S.S. n. 4 “Alto Vicentino
Prodotti citati / Cited products: REALQUALITY RS-CHLAM T
Absence of human parvovirus B19 DNA in myoepithelial sialadenitis of primary Sjögren’s syndrome.
De Re V, De Vita S, Battistella V, Marzotto A, Libra M, Ferraccioli G, Boiocchi M.
Prodotto citato/Cited product: AMPLIQUALITY RS-PARVO B19
Poster: Comparison of five automated CE/IVD labeled HPV DNA genotyping test systems
Michael Bozic, Christoph Koidl, Harald H. Kessler and Egon Marth.
Prodotto citato / Cited product: AMPLIQUALITY HPV TYPE
Workshop teorico-pratico: “Nuovo approccio di screening e tipizzazione del Papilloma Virus Umano”
Relatore: Mason S.; Lapucci C.
Prodotti citati / Cited products: REALQUALITY RI-HPV STAR, AMPLIQUALITY HPV TYPE HR
Prevalence and type distribution of Human Papillomaviruses types in women with abnormal cytology results in Greece.
I. Dendrinos, E.T. Piperaki, N. Spanakis, V. Pitiriga, A. Antsaklis,A. Tsakris.
Prodotti citati / cited Products: AMPLIQUALITY HPV HS BIO, AMPLIQUALITY HPV TYPE
Poster : “Ricerca del Papilloma Virus Umano in Campioni Istologici Mediante Real Time PCR”
Autori: Piovan M., Pomarè Montin D., Mason S., Gani A., Bortolozzo K., Brusauro F., Lapucci C.
Prodotti citati / Cited products: REALQUALITY RI-HPV STAR, AMPLIQUALITY HPV TYPE HR
Prevalence and genotype distribution of human papillomavirus in non-neoplastic cervical tissue lesion: cervical erosion.
Bayram A, Erkılıç S, Balat Ö, Ekşi F, Uğur MG, Öztürk E, Kaya G.
Prodotti citati / cited Products: AMPLIQUALITY HPV HS BIO, AMPLIQUALITY HPV TYPE
Human papilloma virus (HPV) molecular diagnostics.
Kroupis C, Vourlidis N.
Prodotto citato / Cited product: AMPLIQUALITY HPV HS BIO
Detection and genotyping of human papillomavirus in gynaecologic outpatients of Messina, eastern Sicily, Italy.
Giuffrè G, Simone A, Todaro P, Le Donne M, Caruso C, Pizzo A, Granese D.
Prodotti citati / Cited products: AMPLIQUALITY HPV HS Bio, AMPLIQUALITY HPV TYPE
Human papillomavirus typing of invasive cervical cancers in Italy.
Del Mistro A, Salamanca HF, Trevisan R, Bertorelle R, Parenti A, Bonoldi E, Zambon P, Minucci D.
Prodotti citati / Cited products: AMPLIQUALITY HPV HS Bio, AMPLIQUALITY HPV TYPE
“La Diagnostica Del Papilloma Virus Umano: Metodi Molecolari a Confronto”
Laureanda: Valentina Griggio; Relatore: Prof.A.Negro; Correlatore: dott.ssa K.Bortolozzo.
Prodotti citati / Cited products: AMPLIQUALITY HPV HS Bio, AMPLIQUALITY HPV TYPE
“HPV e Carcinoma della Cervice Uterina”
Dottoranda: H. Frayle Salamanca. Coordinatore: Ch.ma Prof.ssa P. Zanovello, Supervisore: Ch.ma Dott.ssa A. Del Mistro
Prodotti citati / Cited products: AMPLIQUALITY HPV HS Bio, AMPLIQUALITY HPV TYPE
Presentazione: Human Papillomavirus typing in gynaecologic outpatients in Messina, Italy.
P. Todaro, A. Simone, M. Barresi, R. Scarfì, C. Caruso, A. Pizzo, M. Le Donne, G. Giuffrè.
Prodotti citati / Cited products: AMPLIQUALITY HPV HS Bio, AMPLIQUALITY HPV TYPE
Presentazione: Prevalenza HPV Nel Triage di Donne Aderenti allo Screening in Italia Centrale
Prof Macallini
Prodotti citati / Cited products: AMPLIQUALITY HPV HS Bio, AMPLIQUALITY HPV TYPE
Detection and genotyping of human papillomavirus DNA in samples from healthy Sardinian patients: a preliminary study.
Montaldo C, Mastinu A, Quartuccio M, Piras V, Denotti G, Pisano E, Orrù G.
Prodotto citato / Cites product: AMPLIQUALITY HPV
Detection of human papillomavirus in temporal bone inverted papilloma by polymerase chain reaction.
Marioni G, Altavilla G, Busatto G, Blandamura S, De Filippis C, Staffieri A.
Prodotto citato / Cited product: AMPLIQUALITY HPV
Human papilloma virus (HPV) genotypes prevalence in a region of South Italy (Apulia)
Coscia MF, Monno R, Ballini A, Mirgaldi R, Dipalma G, Pettini F, Cristallo V, Inchingolo F, Foti C, de Vito D.
Prodotti citati: AMPLIQUALITY HPV HS BIO e AMPLIQUALITY HPV TYPE
Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.
Carozzi FM, Burroni E, Bisanzi S, Puliti D, Confortini M, Giorgi Rossi P, Sani C, Scalisi A, Chini F.
Prodottio citato / cited Product: AMPLIQUALITY HPV HS BIO
Rinvenimento di papillomavirus (HPV) genotipo 82 ad alto rischio e della proteina e7 in un carcinoma della laringe
Autori: A.Giannattasio, M.Ricciardi, M.Sarnataro, G.Panetti, M.Panetti, D.Fierro, M.Ferretti, K.Bortolozzo, F.Morelli
Prodotto citato / Cited product: AMPLIQUALITY HPV TYPE
Abstract A12 :Comparison of a novel Real Time PCR/Reverse Line Blot-based technique and the digene HC2 Assay for detection of high-risk HPV genotypes in cervical samples.
S Mason, A Gani, M Vettorato, G Negri, C Mian, F Brusauro, K Bortolozzo
Oral presentation at: ISMD 2012 – Ninth International Symposium on Molecular Diagnostics, Campus of University of Graz, RESOWI-Center (CE), 17-19 Maggio 2012.
Prodotti citati / cited products: REALQUALITY RI HPV STAR, AMPLIQUALITY HPV TYPE
Poster: “Papilloma Virus Umano e Genotipi non Tipizzabili: Quali Opportunità di Detection”.
Autori: F. Brusauro, A.Gani, S.Mason, G.Giuffrè, F.Acciai, K.Bortolozzo.
Prodotto citato / cited Product: AMPLIQUALITY HPV-TYPE EXPRESS v3.0
HPV Model: From Gender Medicine to Healthcare of the Couple.
Zappacosta R, Caraceni D, Melatti G, Gatta DMP, Capanna S, et al.
Prodotti citati / cited Products: AMPLIQUALITY HPV HS BIO, AMPLIQUALITY HPV-TYPE
Ruolo dell’HPV nell’Infertilità Maschile
Dottorando: Dott. Damiano Pizzol, Tutor: Prof.ssa Loredana Gandini, Prof.Carlo Foresta
Dipart.Medicina Sperimentale, Università degli Studi di Roma “La Sapienza”.
Prodotti citati / cited products: AMPLIQUALITY HPV-TYPE EXPRESS V3.0
Human papillomavirus proteins are found in peripheral blood and semen Cd20+ and Cd56+ cells during Hpv-16 semen infection.
Foresta C, Bertoldo A, Garolla A, Pizzol D, Mason S, Lenzi A, De Toni L.
Prodotto citato / cited Product: AMPLIQUALITY HPV-TYPE EXPRESS V3.0
Poster (n.128): “Studio retrospettivo dell’incidenza di HPV in biopsie paraffinate cervico-vaginali”.
Autori: Franchina C, Costanzo C.M., Scalisi N.M., Palermo C.I., Russo R., Laudani M.C., Scalia G.
Prodotto citato / cited Product: AMPLIQUALITY HPV-HS Bio
Poster nr 156: “Identificazione e tipizzazione del Papillomavirus Umano: sviluppo di un nuovo test molecolare”.
Autori: Mason S., Brusauro F., Gani A., Stellin I., Turconi P., Acciai F., Bortolozzo K.
Prodotti citati / cited Products: AMPLIQUALITY HPV-TYPE EXPRESS V3.0, AMPLIQUALITY HPV-TYPE HS BIO
Poster (P4-4): “Comparison between nested and single-step PCR for high sensitivity detection of Human Papillomavirus”
Autori: Mason S, Brusauro F, Gani A, Stellin I, Bortolozzo K.
Prodotti citati / cited Products: AMPLIQUALITY HPV-TYPE EXPRESS V3.0, AMPLIQUALITY HPV-TYPE HS BIO
Identificazione e tipizzazione del Papillomavirus Umano (HPV): sviluppo di un nuovo test molecolare.
Laureanda: Ilaria Stellin; Relatore: Prof. Andrea Trevisan, Correlatore: Dr.ssa Silvia Mason, Dr.ssa Federica Brusauro
Prodotti citati / cited products: AMPLIQUALITY HPV-TYPE EXPRESS, AMPLIQUALITY HPV-TYPE HR
Poster nr 107: Valutazione dell’incidenza dell’infezione da HPV in una popolazione maschile pugliese.
Del Prete R., Capolongo C., Miragliotta L., Miragliotta G.
Prodotti citati / cited Products: AMPLIQUALITY HPV TYPE, AMPLIQUALITY HPV HS Bio
Abstract 164: Detection of high-risk HPV genotypes in cervical samples: a comparison study of a novel Real Time PCR/Reverse Line Blot-based technique and the digene HC2 Assay.
S Mason, A Gani, M Vettorato, G Negri, C Mian, F Brusauro, K Bortolozzo
Poster presentation at: Congresso Nazionale di Citopatologia SIAPEC – IAP, Trieste, 28-30 giugno 2012
Prodotti citati / cited products: REALQUALITY RI HPV STAR, AMPLIQUALITY HPV TYPE
Studio comparativo sulla diagnostica molecolare delle infezioni da Papillomavirus Umano: Real Time PCR/Reverse Line Blot e Hybrid Capture 2 a confronto.
Laureanda: Marianna Vettorato; Relatore: Prof.ssa Elisa Avitabile, Correlatore: Dr.ssa Silvia Mason
Prodotti citati / cited products: REALQUALITY RI HPV STAR, AMPLIQUALITY HPV TYPE, AMPLIQUALITY HPV SM
Valutazione della fase pre-analitica e post-analitica nell’era della diagnosi molecolare delle malattie sessualmente trasmesse: controllo di cellularità e controllo interno.
L.Bianchi, Z.Napoli, S.Turrisi, S.Donati, R.Lari
Prodotto citato / cited Product: AMPLIQUALITY HPV-TYPE EXPRESS v3.0
Pancreatic function assessment.
Laterza L, Scaldaferri F, Bruno G, Agnes A, Boškoski I, Ianiro G, Gerardi V, Ojetti V, Alfieri S, Gasbarrini A.
Prodotto citato / cited Product: 13C BREATH TEST: SUBSTRATI
L’Urea Breath Test (UBT) per la diagnosi dell’infezione da H.pylori, considerazioni cliniche e confronto tra UBT standard e modalità “fast”.
Prodotto citato / Cited product: BREATHQUALITY UBT (cod 11-75).
Usefulness of 13-C urea breathtest in the diagnosis of gastric Helicobacter pilori infection.
M.M. D’Elios, A.Amedei, M.Benagiano, A.Azzurri, e G.Del Prete.
Prodotto citato / Cited product: BREATHQUALITY UBT (cod 11-75)
Novel Monoclonal Antibody-Based Helicobacter pylori Stool Antigen Test
Dore MP, Negrini R, Tadeu V, Marras L, Maragkoudakis E, Nieddu S, Simula L, Cherchi GB, Massarelli G, Realdi G.
Prodotto citato / Cited product: BREATHQUALITY UBT (cod 11-75)
Non-invasive diagnosis of Helicobacter pylori infection: simplified 13C-urea breath test, stool antigen testing, or DNA PCR in human feces in a clinical laboratory setting?
Zambon CF, Basso D, Navaglia F, Mazza S, Razetti M, Fogar P, Greco E, Gallo N, Farinati F, Rugge M, Plebani M.
Prodotto citato / Cited product: BREATHQUALITY UBT
Immunity markers in patients with Helicobacter pylori infection: effect of eradication.
Dore MP, Fastame L, Tocco A, Negrini R, Delitala G, Realdi G.
Prodotto citato / Cited product: BREATHQUALITY UBT (cod 11-75)
Is there anything to the reported association between Helicobacter pylori infection and autoimmune thyroiditis?
Tomasi PA, Dore MP, Fanciulli G, Sanciu F, Realdi G, Delitala G.
Prodotto citato / Cited product: BREATHQUALITY UBT (cod 11-75)
DNA sequences and proteic antigens of H. pylori in cholecystic bile and tissue of patients with gallstones.
Neri V, Margiotta M, de Francesco V, Ambrosi A, Valle ND, Fersini A, Tartaglia N, Minenna MF, Ricciardelli C, Giorgio F, Panella C, Ierardi E.
Prodotto citato / Cited product: BREATHQUALITY UBT (cod 11-75)
Accuracy of breath tests using low doses of 13C-urea to diagnose Helicobacter pylori infection: a randomised controlled trial
L Gatta, C Ricci, A Tampieri, J Osborn, F Perna, V Bernabucci and D Vaira.
Prodotto citato / Cited product: BREATHQUALITY UBT (cod 11-75)
Infezioni da H.pylori associate a Tiroidite ed Orticaria Cronica: follow-up con urea breathtest e spettrometria di massa isotopica.
C.D’Amario, A.Di Sante, G.Fiore, M.Cervone, B.Raggiunti.
Prodotto citato / Cited product: BREATHQUALITY UBT (cod 11-75)
Diagnostic accuracy of a rapid fecal test to confirm H pylori eradication after therapy: prospective comparison with a laboratory stool test.
Trevisani L, Cifalà V, Fusetti N, Gilli G, Tombesi P, Torchiaro M, Boccia S, Abbasciano V.
Prodotto citato / Cited product: BREATHQUALITY UBT (cod 11-75)
Clarithromycin Resistance, Tumor Necrosis Factor Alpha Gene Polymorphism and Mucosal Inflammation Affect H. pylori Eradication Success
Zambon CF, Fasolo M, Basso D, D’Odorico A, Stranges A, Navaglia F, Fogar P, Greco E, Schiavon S, Padoan A, Fadi E, Sturniolo GC, Plebani M, Pedrazzoli S.
Prodotto citato / Cited product: BREATHQUALITY UBT (cod 11-75)
Inhibition of Helicobacter pilori Infection in Humans by Lactobacillus reuteri ATCC 55730 and Effect on Eradication Therapy: A Pilot Study
Francavilla R, Lionetti E, Castellaneta SP, Magistà AM, Maurogiovanni G, Bucci N, De Canio A, Indrio F, Cavallo L, Ierardi E, Miniello VL
Prodotto citato / Cited product: BREATHQUALITY UBT (cod 11-75)
Pancreatic function assessment.
Laterza L, Scaldaferri F, Bruno G, Agnes A, Boškoski I, Ianiro G, Gerardi V, Ojetti V, Alfieri S, Gasbarrini A.
Prodotto citato / cited Product: 13C BREATH TEST: SUBSTRATI
AB ANALITICA partners in DECIDER project to improve diagnostics and treatment of ovarian cancer with the help of AI – 15 million euros in funding from the EU
The goal of the 5-year research project is to discover novel diagnostic tools and effective drug combinations based on data from high-grade serous ovarian cancer patients. Partners in this international and multidisciplinary project come from 14 organisations in seven EU countries.
The European Union has funded a project to improve personalized treatments for ovarian cancer with nearly 15 million euros for five years. The international DECIDER project has partners from 14 organizations in seven EU countries.
In Europe, over 40.000 women die of ovarian cancer every year. In addition to surgery, most patients are treated with platinum-based chemotherapy. Unfortunately, the effect of the chemotherapy often decreases during the treatment cycles, and currently there are few effective treatments to those patients who develop resistance to platinum-based drugs.
The project starts in February and will develop diagnostic tools to identify earlier and more reliably patients whose cancer is not responding to the current treatments. The research also aims to discover effective combination treatments based on the data measured from the tumours.
“Cancer is one of the leading causes of mortality in the world and as the population ages, the incidence of cancers will only increase. Any new tools that enable better and more targeted treatment of cancers in the future will not only decrease the amount of human suffering, but also the burden on healthcare,” says Sampsa Hautaniemi, a professor at the University of Helsinki and coordinator of the DECIDER project.
Artificial intelligence to integrate and visualise patient information for doctors
In the project, a patient’s response to treatments is predicted using methods, which use, among others, histopathological and genomic data from the patient. Genomic changes and aberrations in gene functions are used to find effective, personalized treatments.
“We will develop an open source program, which will integrate and visualize all relevant data from a patient. Using this information, doctors can more easily identify effective drugs for their patient,” says Hautaniemi, whose research group works in the project on method development as well as analysis, integration and interpretation of the data measured from the tumours.
An important part of the project is collaboration with SMEs in developing, producing and registering diagnostic kits, producing a drug-sensitivity test based on the tumour tissue samples, developing image based diagnostics of digital samples, and developing data pseudonymisation and anonymisation techniques necessary for the management of sensitive patient data for privacy risk protection.
AB ANALITICA, as a developer and manufacturer of IVD (In Vitro Diagnostics) devices compliant with the applicable regulations, consisting of reagent kits for performing nucleic acid molecular testing assays and related equipment and software, is involved in the development and subsequent production and marketing of diagnostic kits for performing the drug-sensitivity tests.
Legal researchers address ethical and legal concerns
In addition to medical research, the project also includes a legal work package that addresses the ethical and legal concerns that may arise in the project. Furthermore, the legal researchers will also study whether there are inconsistencies between the pharmaceutical regulatory system and other relevant legislation.
“Our aim is to overcome legal challenges that impede or slow down the provision of new treatments for chemotherapy resistance in high-grade serous ovarian cancer patients. We want to facilitate the commercialisation and availability of personalized therapies in an ethically and legally sustainable manner,” says Professor Päivi Korpisaari.
DECIDER partners and persons in charge of the research
DECIDER (Clinical Decision via Integrating Multiple Data Levels to Overcome Chemotherapy Resistance in High-Grade Serous Ovarian Cancer) partners and persons in charge of the research:
University of Helsinki, Finland (Sampsa Hautaniemi, Olli Carpén, Päivi Korpisaari)
Hospital District of Southwest Finland (Johanna Hynninen)
HUS Helsinki University Hospital, Finland (Anni Virtanen)
Karolinska Institutet, Sweden (Jussi Taipale)
Danish Cancer Society, Denmark (Tuula Kallunki)
Heidelberg University Hospital, Germany (Julio Saez-Rodriguez)
Institut Pasteur, France (Benno Schwikowski)
University of Modena and Reggio Emilia, Italy (Elisa Ficarra)
Insitute for Research in Biomedicine, Spain (Fran Supek)
Barcelona Supercomputing Center, Spain (Salvador Capella)
Aiforia Technologies Oy, Finland (Kaisa Helminen)
VEIL.AI Ltd, Finland (Tuomo Pentikäinen)
2cureX A/S, Denmark (Ole Thastrup)
AB ANALITICA SRL (Diego Boscarino)
In advisory role representing cancer patients viewpoint: Cancer Society of Finland and Association of Cancer Patients in Finland.
The project has been funded by European Union’s Horizon 2020 research and innovation programme under grant agreement No 965193.
Further information from:
Sampsa Hautaniemi, professor, University of Helsinki
Phone. +358 50 448 63 20
Email: sampsa.hautaniemi@helsinki.fi
Read more about the project from the DECIDER website.
Project Twitter account: @deciderproject
AB ANALITICA part of the decades-long cooperation with the company DOTT DINO PALADIN is pleased to announce the realization of this new Interreg Italia-Slovenija project by the company DOTT DINO PALADIN. In the future this project could give rise to a new realization of innovative in vitro devices.
Interreg Italia-Slovenija
DIAGNOSIS OF PROSTHETIC INFECTIONS IN ORTHOPEDICS WITH INNOVATIVE METHODS BASED ON THE USE OF BACTERIOPHAGES
Standard project co-financed by the European Regional Development Fund
The aim is to design a diagnostic test for bacterial detection within the sonication fluid from an infected prosthetic joint using an optimized suspension of specific phages.
The Scientific Research Center DOTT. DINO PALADIN is partner of the project.
EU funds ovarian cancer research with 6 million euros
An international collaboration project to study drug resistance in ovarian cancer has received 6 million euros for five years from the EU Horizon 2020 Research and Innovation program. The project is coordinated from the University of Helsinki, Finland, and begins on January 1, 2016.
The HERCULES project focuses on the most common and most difficult to treat subtype of ovarian cancer, high-grade serous ovarian cancer. These tumors consist of several heterogeneous cell populations with a large number of mutations. This genetic variability of the tumors makes it difficult to find drugs that would be able to kill all the cancer cells and to which some of the cells would not become resistant during treatment.
Although most patients respond well to current treatments initially, more than half of them experience relapse. In Europe more than 40 000 women die of ovarian cancer every year.
In the HERCULES project, the tumors are analyzed in an unprecedented level of detail to discover which cell populations the tumors consist of, how they respond to treatments and what makes them resistant to treatments.
Patient samples are used to study the function of genes and proteins at a single-cell level by using the latest mass cytometry, sequencing and computational methods. The researchers aim to find an optimal set of biomarkers that can be used to identify different cell populations from tissue samples. Fresh tissue samples and cell lines will be used to study the tumor cells’ response to several drug compounds.
The results from these experiments will be used in computational modelling and development of computational tools to predict which drug compounds will target each cell population best. Based on this information, the aim is to develop a test that can be used to predict which drug combinations will be most efficient against an individual patient’s cancer.
The results of the project will help doctors in finding the best treatments to each ovarian cancer patient.
In addition to coordinating the project, University of Helsinki researchers are responsible for sample sequencing, data analysis, development of computational tools, single-cell sequencing and drug response experiments. Other partners in Finland are from the University of Turku and the Hospital District of South-West Finland. They are in charge of recruiting patients, collecting and processing the samples and establishing cell lines.
Network modeling for the project is performed at the Institute of Pasteur in France and identification and sorting of cell populations at the Istituto Superiore di Sanità in Italy. Gene regulation and expression studies are done at the Karolinska Institutet in Sweden. Validation of the results and predictions will be done in Italy at the University of Trieste and in Finland at the Universities of Helsinki and Turku by using biobank samples, cell lines and experimental models. The test for drug response prediction will be developed by AB Analitica, an Italian SME.
Additional information:
www.project-hercules.eu
hercules@helsinki.fi
Tiia Pelkonen, Project manager
+358 50 3199520
tiia.pelkonen@helsinki.fi
Sampsa Hautaniemi, Project coordinator
+358 50 336 4765
sampsa.hautaniemi@helsinki.fi
Project partners
University of Helsinki, Finland
– Sampsa Hautaniemi
– Anna Vähärautio
– Tero Aittokallio
– Krister Wennerberg
Hospital District of South-West Finland
– Seija Grénman
University of Turku, Finland
– Olli Carpén
University of Trieste, Italy
– Giorgio Stanta
Istituto Superiore di Sanità, Italy
– Mauro Biffoni
– Luca Pasquini
Karolinska Institutet, Sweden
– Jussi Taipale
Institute Pasteur, France
– Benno Schwikowski
AB ANALITICA SRL, Italy
– Dino Paladin
